Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 122, Issue 5, 2003, Pages 788-794

  Uzunel, Mehmet ^a   Jaksch, Marie ^a   Mattsson, Jonas ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukaemia; Minimal residual disease; Relapse; Stem cell transplantation

Indexed keywords

IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MALE; MEDICAL ASSESSMENT; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS OF VARIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT, T-LYMPHOCYTE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; POSTOPERATIVE PERIOD; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0041911489     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04495.x     Document Type: Article

References (33)

1. Bader, P., Klingebiel, T., Schaudt, A., Theurer-Mainka, U., Handgretinger, R., Lang, P., Niethammer, D. & Beck, J.F. (1999) Prevention of relapse m pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children, Leukemia, 13, 2079-2086.
2. Bader, P., Hancock, J., Kreyenberg, H., Goulden, N.J., Niethammer, D., Oakhill, A., Steward, C.G., Handgretinger, R., Beck, J.F. & Klingebiel, T. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668-1672.
3. Brisco, J., Hughes, E., Neoh, S.H., Sykes, P.J., Bradstock, K., Enno, A., Szer, J., McCaul, K. & Morley, A.A. (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood, 87, 5251-5256.
4. Carlens, S., Remberger, M., Aschan, J. & Ringden, O. (2001) The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biology of Blood and Marrow Transplantation, 7, 31-38.
5. Collins, Jr, R.H., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. & Nemunaitis, J. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433-444.
6. Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691-2696.
7. Coustan-Smith, E., Sancho, J., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. & Campana, D. (2002) Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 100, 2399-2402.
8. Dazzi, F., Szydlo, R.M., Cross, N.C., Craddock, C., Kaeda, J., Kanfer, E., Cwynarski, K., Olavarria, E., Yong, A., Apperley, J.F. & Goldman, J.M. (2000) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 96, 2712-2716.
9. van Dongen, J.J., Seriu, T., Panzer-Grumayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood (see comments). Lancet, 352, 1731-1738.
10. Foroni, L., Coyle, L.A., Papaioannou, M., Yaxley, J.C., Sinclair, M.F., Chim, J.S., Cannell, P., Secker-Walker, L.M., Mehta, A.B., Prentice, H.G. & Hoffbrand, A.V. (1997) Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaeima reveals differences in treatment response. Leukemia, 11, 1732-1741.
11. de Haas, V., Vet, R.J., Verhagen, O.J., Kroes, W., van den Berg, H. & van der Schoot, C.E. (2002) Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia. Annals of Hematology, 81, 59-61.
12. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, E.E. & Bortin, M.M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
13. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998a) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072-4079.
14. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Harris, E.L., Garland, R.J., Jones, C.G., Grandage, V.L., Rowbottom, A.W., Green, A.F., Clarke, E., Lankester, A.W., Potter, M.N., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998b) Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. British Journal of Haematology, 102, 860-871.
15. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. & Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-2465.
16. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E. & Ansari, H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 86, 2041-2050.
17. Matsue, K., Tabayashi, T., Yamada, K. & Takeuchi, M. (2002) Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplantation, 29, 63-66.
18. Mattsson, J., Uzunel, M., Remberger, M., Ljungman, P., Kimby, E., Ringden, O. & Zetterquist, H. (2000) Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia, 14, 247-254.
19. Miglino, M., Berisso, G., Grasso, R., Canepa, L., Clavio, M., Pierri, I., Pietrasanta, D., Gatto, S., Varaldo, R., Ballerini, F., Verdiani, S., Casarino, L., DeStefano, F., Sessarego, M., Dominietto, A., Ralola, A.M., Bregante, S., di Grazia, C., Gobbi, M. & Bacigalupo, A. (2002) Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplantation, 30, 579-585.
20. Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. & Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 1094-1104.
21. Pongers-Willemse, M.J., Seriu, T., Stolz, F., d'Aniello, E., Gameiro, P., Pisa, P., Gonzalez, M., Bartram, C.R., Panzer-Grumayer, E.R., Biondi, A., San Miguel, J.F. & van Dongen, J.J. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 110-118.
22. Radich, J., Ladne, P. & Gooley, T. (1995) Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biology of Blood and Marrow Transplantation, 1, 24-31.
23. Radich, J., Gehly, G., Lee, A., Avery, R., Bryant, E., Edmands, S., Gooley, T., Kessler, P., Kirk, J., Ladne, P., Thomas, E.D. & Appelbaum, F.R. (1997) Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation, Blood, 89, 2602-2609.
24. van Rhee, F., Lin, F., Cullis, J.O., Spencer, A., Cross, N.C., Chase, A., Garicochea, B., Bungey, J., Barrett, J. & Goldman, J.M. (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood, 83, 3377-3383.
25. Ringden, O., Pihlstedt, P., Markling, L., Aschan, J., Baryd, I., Ljungman, P., Lonnqvist, B., Tollemar, I., Janossy, G. & Sundberg, B. (1991) Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplantation, 7, 221-226.
26. Ringden, O., Remberger, M., Persson, U., Ljungman, P., Aldener, A., Andstrom, E., Aschan, J., Bolme, P., Dahllof, G., Dalianis, T., Gahrton, G., Hagglund, H., Lonnqvist, B., Olerup, O., Shanwell, A., Sparrelid, E., Winiarski, J., Moller, E. & Oberg, M. (1995) Similar incidence of graft-versus-host disease using HLA-A-B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplantation, 15, 619-625.
27. Ringden, O., Labopin, M., Gluckman, E., Reiffers, J., Vernant, J.P., Jouet, J.P., Harrousseau, J.L., Fiere, D., Bacigalupo, A., Frassoni, F. & Gorin, N.C. (1996) Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 18, 921-929.
28. Sanchez, J., Serrano, J., Gomez, P., Martinez, F., Martin, C., Madero, L., Herrera, C., Garcia, J.M., Casano, J. & Torres, A. (2002) Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology, 116, 686-694.
29. Szczepanski, T., Willemse, M.J., Brinkhof, B., van Wering, E.R., van der Burg, M. & van Dongen, J.J. (2002) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 99, 2315-2323.
30. Uzunel, M., Mattsson, J., Jaksch, M., Remberger, M. & Ringden, O. (2001) The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood, 98, 1982-1984.
31. van der Velden, V.H., Joosten, S.A., Willemse, M.J., van Wering, E.R., Lankester, A.W., van Dongen, J.J. & Hoogerbrugge, P.M. (2001) Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 15, 1485-1487.
32. van der Velden, V.H., Jacobs, D.C., Wijkhuijs, A.J., Comans-Bitter, W.M., Willemse, M.J., Hahlen, K., Kamps, W.A., van Wering, E.R. & van Dongen, J.J. (2002) Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 16, 1432-1436.
33. Zetterquist, H., Mattsson, J., Uzunel, M., Näsman-Björk, I., Svenberg, P., Tammik, L., Bayat, G., Winiarski, J. & Ringden, O. (2000) Mixed chimerism in the B-cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B-cell acute lymphoblastic leukemia. Bone Marrow Transplantation, 25, 843-851.